PE2I: A radiopharmaceutical for in vivo exploration of the dopamine transporter

CNS Neuroscience and Therapeutics

Volumn 14, Issue 1, 2008, Pages 47-64

  Emond, Patrick ^a,c   Guilloteau, Denis ^b,c   Chalon, Sylvie ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Brain; DAT; Dopamine; Dopamine transporter; Imaging; Parkinson's disease; PE21; PET; SPECT

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARBON; COCAINE; DOPAMINE TRANSPORTER; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; NISOXETINE; PAROXETINE; PE21 C 11; PE21 I 125; RADIOPHARMACEUTICAL AGENT; SULPIRIDE; TRITIUM; UNCLASSIFIED DRUG; VANOXERINE; N (3 IODOPROP 2 ENYL) 2 BETA CARBOMETHOXY 3 (4 METHYLPHENYL)NORTROPANE; N-(3-IODOPROP-2-ENYL)-2-BETA-CARBOMETHOXY-3-(4-METHYLPHENYL)NORTROPANE; NORTROPANE DERIVATIVE; IODINE; N (3 IODOPRO 2 EPSILON ENYL) 2 BETA CARBOXYMETHOXY 3 BETA (4' METHYLPHENYL) NORTROPANE;

ATTENTION DEFICIT DISORDER; AUTORADIOGRAPHY; BASAL GANGLION; BINDING AFFINITY; BINDING SITE; CONTINUOUS INFUSION; CORPUS STRIATUM; DOSIMETRY; DRUG BINDING; DRUG INHIBITION; DRUG SELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR IMAGING; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RADIATION EXPOSURE; RADIOACTIVITY; RADIOCHEMISTRY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; ANIMAL; METABOLISM; BRAIN CORTEX; CADAVER; DRUG EFFECT; HEMISPHERE; IN VITRO STUDY; NEUROIMAGING; NEUROTOXICITY;

ANIMALS; AUTORADIOGRAPHY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; NORTROPANES; RADIOPHARMACEUTICALS;

EID: 47149108159     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2007.00033.x     Document Type: Review

References (78)

1. Acton PD, Kushner SA, Kung MP, Mozley PD, Plossl K, Kung HF (1999) Simplified reference region model for the kinetic analysis of [99mTc]TRODAT-1 binding to dopamine transporters in nonhuman primates using single-photon emission tomography. Eur J Nucl Med 26 : 518 526.
2. Asenbaum S, Brucke T, Pirker W, Podreka I, Angelberger P, Wenger S, Wober C, Muller C, Deecke L (1997) Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 381 : 1 6.
3. Barc S, Page G, Barrier L, Garreau L, Guilloteau D, Fauconneau B, Chalon S (2002) Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat. J Neurochem 80 : 365 374.
4. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, et al. 2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 15 : 503 510.
5. Berthommier E, Loc'h C, Chalon S, Olivier C, Emond P, Dao Boulanger H, Lelait MA, Mauclaire L (2002) New preparation of [123I]PE2I: Investigation of the oxidation and purification steps. J Lab Compd Radiopharm 45 : 1019 1028.
6. Bézard E, Boraud T, Chalon S, Brotchie JM, Guilloteau D, Gross CE (2001a) Pallidal border cells: An anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience 103 : 117 123.
7. Bézard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE (2001b) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21 : 6853 6861.
8. Boja JW, Carroll FI, Rahman MA, Philip A, Lewin AH, Kuhar MJ (1990) New, potent cocaine analogs: Ligand binding and transport studies in rat striatum. Eur J Pharmacol 184 : 329 332.
9. Boja JW, Patel A, Carroll FI, Rahman MA, Philip A, Lewin AH, Kopajtic TA, Kuhar MJ (1991) [125I]RTI-55: A potent ligand for dopamine transporters. Eur J Pharmacol 194 : 133 134.
10. Boja JW, Mitchell WM, Patel A, Kopajtic TA, Carroll FI, Lewin AH, Abraham P, Kuhar MJ (1992) High-affinity binding of [125I]RTI-55 to dopamine and serotonin transporters in rat brain. Synapse 12 : 27 36.
11. Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, Janssen AG, Stoof JC, van Royen EA (1998) Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 39 : 1879 1884.
12. Bouchez G, Sensebé L, Garreau L, Besnard JC, Guilloteau D, Charbord P, Chalon S (2007) Graft of adult mesenchymal stem cells cultures in a standard or neuronal differentiation medium in a rat model of Parkinson's disease. 5th Forum of European Neuroscience, abstract.
13. Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I (1993) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 94 : 137 146.
14. Castellanos FX (1997) Toward a pathophysiology of attention-deficit/ hyperactivity disorder. Clin Pediatr (Phila) 36 : 381 393.
15. Catafau AM, Tolosa E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group (2004) Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19 : 1175 1182.
16. Chalon S, Emond P, Bodard S, Vilar MP, Thiercelin C, Besnard JC, Guilloteau D (1999a) Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse 31 : 134 139.
17. Chalon S, Garreau L, Emond P, Zimmer L, Vilar MP, Besnard JC, Guilloteau D (1999b) Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2β- carbomethoxy-3β-(4′-methylphenyl)nortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther 291 : 648 654.
18. Chalon S, Hall H, Saba W, Garreau L, Dollé F, Halldin C, Emond P, Bottlaender M, Deloye J-B, Helfenbein J, et al. 2006) Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2β-carbomethoxy-3β- (4′-tolyl) nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter. J Pharmacol Exp Ther 317 : 147 152.
19. Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI (1995) The dopamine transporter: Immunochemical characterization and localization in brain. J Neurosci 15 : 1714 1723.
20. Cook EH, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL (1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56 : 993 998.
21. Dollé F, Bottlaender M, Demphel S, Emond P, Fuseau C, Coulon C, Ottaviani M, Valette H, Loc'h C, Halldin C, et al. 2000) Highly efficient synthesis of [11C]PE2I, a selective radioligand for the quantification of the dopamine transporter using PET. J Lab Compounds Radiopharm 43 : 997 1004.
22. Dollé F, Emond P, Mavel S, Demphel S, Hinnen F, Mincheva Z, Saba W, Valette H, Chalon S, Halldin C, et al. 2006) Synthesis, radiosynthesis and in vivo preliminary evaluation of [(11)]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. Bioorg Med Chem 14 : 1115 1125.
23. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354 : 2132 2133.
24. Dresel S, Krause J, Krause KH, LaFougere C, Brinkbaumer K, Kung HF, Hahn K, Tatsch K (2000) Attention deficit hyperactivity disorder: Binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27 : 1518 1524.
25. Elfving B, Bjornholm B, Knudsen GM (2003) Interference of anaesthetics with radioligand binding in neuroreceptor studies. Eur J Nucl Med Mol Imaging 30 : 912 915.
26. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, Frangin Y, Mauclaire L, Besnard JC, Guilloteau D (1997) Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4′- iodophenyl) nortropane and N-(3-iodoprop-(2E)-enyl)-2β-carbomethoxy- 3β-(3′,4′-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 40 : 1366 1372.
27. Eshleman AJ, Neve RL, Janowsky A, Neve KA (1995) Characterization of a recombinant human dopamine transporter in multiple cell lines. J Pharmacol Exp Ther 274 : 276 283.
28. Farde L, Ginovart N, Halldin C, Chou YH, Olsson H, Swahn CG (2000) A PET study of [11C]-β-CIT-FE, binding to the dopamine transporter in the monkey and human brain. Int J Neuropsychopharmacol 3 : 203 214.
29. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M (1997) Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 2 : 311 313.
30. Gouhier C, Chalon S, Aubert-Pouessel A, Venier-Julienne MC, Jollivet C, Benoit JP, Guilloteau D (2002) Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse 44 : 124 131.
31. Guilloteau D, Emond P, Baulieu JL, Garreau L, Frangin Y, Pourcelot L, Mauclaire L, Besnard JC, Chalon S (1998) Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2β- carbomethoxy-3β-(4′-methylphenyl)nortropane (PE2I). Nucl Med Biol 25 : 331 337.
32. Hall H, Halldin C, Farde L, Sedvall G (1998) Whole hemisphere autoradiography of the postmortem human brain. Nucl Med Biol 25 : 715 719.
33. Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, Farde L, Sedvall G (1999) Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. Neuroimage 9 : 108 116.
34. Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L (2003) [(11)C]PE2I: A highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 30 : 1220 1230.
35. Halldin C, Farde L, Lundkvist C, Ginovart N, Nakashima Y, Karlsson P, Swahn CG (1996) [11C]β-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. Synapse 22 : 386 390.
36. Inaji M, Okauchi T, Ando K, Maeda J, Nagai Y, Yoshizaki T, Okano H, Nariai T, Ohno K, Obayashi S, et al. 2005a) Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 1064 : 136 145.
37. Inaji M, Yoshizaki T, Okauchi T, Maeda J, Nagai Y, Nariai T, Ohno K, Ando K, Okano H, Obayashi S, et al. 2005b) In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats. Cell Transplant 14 : 655 663.
38. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, et al. 1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90 : 11965 11969.
39. Janowsky A, Berger P, Vocci F, Labarca R, Skolnick P, Paul S (1986) Characterization of sodium-dependent [3H]GBR-12935 binding in brain: A radioligand for selective labelling of the dopamine transport complex. J Neurochem 46 : 1272 1276.
40. Jewett DM (1992) A simple synthesis of [11C]methyl triflate. Int J Rad Appl Instrum [A 43 : 1383 1385.
41. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L (2005) Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57 : 229 238.
42. Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L (2006) Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: A PET study. Eur J Nucl Med Mol Imaging 33 : 657 668.
43. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K (2000) Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285 : 107 110.
44. Kuikka JT, Baulieu JL, Hiltunen J, Halldin C, Bergstrom KA, Farde L, Emond P, Chalon S, Yu M, Nikula T, et al. 1998) Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. Eur J Nucl Med 25 : 531 534.
45. Kung MP, Essman WD, Frederick D, Meegalla S, Goodman M, Mu M, Lucki I, Kung HF (1995) IPT: A novel iodinated ligand for the CNS dopamine transporter. Synapse 20 : 316 324.
46. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS, Neumeyer JL, Charney DS, Hoffer PB, Innis RB (1994) Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14 : 982 994.
47. Leroy C, Comtat C, Trebossen R, Syrota A, Martinot JL, Ribeiro MJ (2007) Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med 48 : 538 546.
48. Lundkvist C, Halldin C, Ginovart N, Swahn C-G, Farde L (1997) [18F][beta]-CIT-FP is superior to [11C][beta]-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol 24 : 621 627.
49. Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA (1989) Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane. Mol Pharmacol 36 : 518 524.
50. Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, Bezard E (2003) Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol Neurobiol 28 : 209 218.
51. Morrish PK (2003) How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord 18 : S63 S70.
52. Page G, Chalon S, Emond P, Maloteaux JM, Hermans E (2002) Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β- (4′-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells. Neurochem Int 40 : 105 113.
53. Pinborg LH, Videbaek C, Svarer C, Yndgaard S, Paulson OB, Knudsen GM (2002) Quantification of [(123)I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging 29 : 623 631.
54. Pinborg LH, Ziebell M, Frokjaer VG, de Nijs R, Svarer C, Haugbol S, Yndgaard S, Knudsen GM (2005) Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med 46 : 1119 1127.
55. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, Brucke T (2002) Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study. Mov Disord 17 : 45 53.
56. Poyot T, Conde F, Gregoire MC, Frouin V, Coulon C, Fuseau C, Hinnen F, Dolle F, Hantraye P, Bottlaender M (2001) Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: Comparison with 6-[18F]fluoro-L-dopa. J Cereb Blood Flow Metab 21 : 782 792.
57. Prunier C, Bezard E, Montharu J, Mantzarides M, Besnard JC, Baulieu JL, Gross C, Guilloteau D, Chalon S (2003a) Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT. Neuroimage 19 : 810 816.
58. Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, Tafani M, Bezard E, Esquerre JP, Baulieu JL (2003b) Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease. J Nucl Med 44 : 663 670.
59. Ribeiro MJ, Ricard M, Lievre MA, Bourgeois S, Emond P, Gervais P, Dolle F, Syrota A (2007) Whole-body distribution and radiation dosimetry of the dopamine transporter radioligand [(11)C]PE2I in healthy volunteers. Nucl Med Biol 34 : 465 470.
60. 11C]LBT-999: A suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse 61 : 17 23.
61. Seeman P, Madras BK (1998) Antihyperactivity medication: Methylphenidate and amphetamine. Mol Psychiatry 3 : 386 396.
62. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, et al. 1995) Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 38 : 589 598.
63. Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB (1997) Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 38 : 1453 1459.
64. Shetty HU, Zoghbi SS, Liow JS, Ichise M, Hong J, Musachio JL, Halldin C, Seidel J, Innis RB, Pike VW (2007) Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [(11)C]PE2I. Eur J Nucl Med Mol Imaging 34 : 667 678.
65. Solanto MV (1984) Neuropharmacological basis of stimulant drug action in attention deficit disorder with hyperactivity: A review and synthesis. Psychol Bull 95 : 387 409.
66. Stepanov V, Jarv J (2006) Slow isomerization step in the interaction between mouse dopamine transporter and dopamine re-uptake inhibitor N-(3-iodoprop-2E-enyl)-2β-carbo-[3H]methoxy-3β-(4′-methylphenyl) nortropane. Neurosci Lett 410 : 218 221.
67. Stepanov V, Schou M, Jarv J, Halldin C (2007) Synthesis of 3H-labeled N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methylphenyl)nortropane (PE2I) and its interaction with mice striatal membrane fragments. Appl Radiat Isot 65 : 293 300.
68. Strickland S, Palmer G, Massey V (1975) Determination of dissociation constants and specific rate constants of enzyme-substrate (or protein-ligand) interactions from rapid reaction kinetic data. J Biol Chem 250 : 4048 4052.
69. Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S, Murias M, Moriarity J, Barr C, Smith M, et al. 2000) Dopamine genes and ADHD. Neurosci Biobehav Rev 24 : 21 25.
70. Tupala E, Kuikka JT, Hall H, Bergstrom K, Sarkioja T, Rasanen P, Mantere T, Hiltunen J, Vepsalainen J, Tiihonen J (2001) Measurement of the striatal dopamine transporter density and heterogeneity in type I alcoholics using human whole hemisphere autoradiography. Neuroimage 14 : 87 94.
71. Tupala E, Hall H, Bergstrom K, Mantere T, Rasanen P, Sarkioja T, Hiltunen J, Tiihonen J (2003) Different affect of age on dopamine transporters in the dorsal and ventral striatum of controls and alcoholics. Synapse 48 : 205 211.
72. Tupala E, Halonen P, Tiihonen J (2006) Visualization of the cortical dopamine transporter in type I and 2 alcoholics with human whole hemisphere autoradiography. Eur Neuropsychopharmacol 16 : 552 560.
73. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F (1994) Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 35 : 494 498.
74. Van Dick CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, Seibyl JP, Innis RB (2002) Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. Am J Psychiatry 159 : 309 312.
75. Vizi ES (2000) Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol Rev 52 : 63 89.
76. Wall SC, Innis RB, Rudnick G (1993) Binding of the cocaine analog 2β-carbomethoxy-3β-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters: Different ionic requirements for substrate and 2β-carbomethoxy-3β-(4- [125I]iodophenyl)tropane binding. Mol Pharmacol 43 : 264 270.
77. Ziebell M, Thomsen G, Knudsen GM, de Nijs R, Svarer C, Wagner A, Pinborg LH (2007) Reproducibility of [(123)I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging 34 : 101 109.
78. Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS, Shah J, Musachio JL, Pike VW, Innis RB (2006) PET imaging of the dopamine transporter with 18F-FECNT: A polar radiometabolite confounds brain radioligand measurements. J Nucl Med 47 : 520 527.